Medtronic's Hugo RAS System Gains Momentum with New FDA Submissions, Challenging Da Vinci's Dominance

01

Escalation of the Surgical Robot Wars

MedtronicAnnouncementHugoSignificant Advances

Medtronic Announces Significant Advances in Surgical Robotics

Since its approval in 2021, the Hugo RAS system has been utilized in tens of thousands of surgical procedures. Last December, Medtronic’s Hugo™ robotic-assisted surgery system received initial FDA clearance for use in urological surgeries. Within months of its official entry into the U.S. market, it has already been deployed for commercial use at multiple leading medical institutions across the United States.

Currently, the indications for the Hugo™ robotic system in the United States are expected to expand further. It is understood thatMedtronic has submitted a 510(k) application to expand the Hugo™ robotic-assisted surgery system into the fields of general surgery and gynecology in the United States。

The 510(k) application for the use of the Hugo RAS system in general surgery and gynecological procedures will significantly expand the clinical application scope of this platform in the United States, meeting the growing demand for robot-assisted minimally invasive treatments in these high-demand specialty areas.

Medtronic has also completed enrollment for the Embrace gynecological medical device clinical trial (IDE) of the Hugo™ RAS system in the United States. Embrace Gynecology is a prospective, multicenter study designed to evaluate the safety and effectiveness of the Hugo™ RAS system in robot-assisted gynecological surgery.

To better meet the specific needs of surgical robots, Medtronic has also upgraded some existing technologies.

Notably, ProGrip™ Advanced has recently received FDA approval. As an upgraded version of existing mesh technology, it is designed to better meet the specific needs of robot-assisted abdominal wall hernia repair.

Additionally, Medtronic has submitted a 510(k) application to the FDA for the LigaSure RAS Maryland device. The LigaSure RAS is specifically designed for the Valleylab™ FT10 energy platform on the Hugo™ RAS system and was launched in Europe last year on the Hugo RAS system.

Is the da Vinci still stable?

After dominating the surgical robot market for over two decades, da Vinci has welcomed its most formidable competitor.

This month, Medtronic released its latest financial report, achieving its strongest annual revenue growth in a decade. The global medical device giant is charging into higher-growth, more innovative territories with unprecedented vigor. Surgical robotics is one of Medtronic’s most prioritized segments.

During the recent earnings season, Medtronic disclosed that its new products—Hugo, Altaviva, Stealth AXiS, and OmniaSecure—made significant contributions.

Currently, the United States is the most mature market for surgical robots globally and a fiercely contested battleground in the surgical robotics industry. It took Medtronic several years after the commercial launch of its Hugo™ robotic system to finally gain a foothold in the U.S. market.

However, this is far from sufficient. MEDTECHDIVE pointed out that last year, U.S. surgeons performed approximately 2 million procedures using the da Vinci robotic systemsurgical procedures. Among these, general surgery accounted for 1.25 million cases, and gynecological surgeries for 468,000 cases. Urological surgery was the smallest of the three major fields for da Vinci robotic applications, with only 201,000 procedures.

If the indications for Hugo™ can be successfully expanded, Medtronic’s surgical robot will engage in direct competition with da Vinci across a broader range of fields.。

From another perspective, the da Vinci system is still in its growth phase.

Intuitive Surgical's latest financial report shows,Q1 2026 Revenue of $2.77 Billion, a 23% Year-on-Year Increase, Exceeding Market ExpectationsAmong these, instrument and accessory revenue grew by 23%, reaching $1.69 billion; system revenue increased by 24%, amounting to $651 million. The adjusted gross profit margin rose from 66.4% to 67.8%.

In the first quarter of this year, 431 da Vinci systems were installed, representing a 17% year-over-year increase. Of these, 226 were in the United States, 117 in Europe, 62 in Asia, and 26 in other geographic markets.

Focusing on the U.S. market, da Vinci surgical procedure volume increased by approximately 14% in Q1, primarily driven by rapid growth in general surgery procedures—particularly cholecystectomy, hernia repair, and appendectomy—as well as an increase in gynecological surgeries.

As it races ahead in the surgical robotics sector, this industry leader is also feeling the competitive pressure from its pursuers.

In its financial report, Intuitive Surgical listed its competitors one by one, including global top-tier companies such as Medtronic and Johnson & Johnson.Shurui, Sizherui, Weigao, MicroPort Medical, and Jingfeng Medical from China are also on the list.。

On the periphery of the battlefield,Mindray and United Imaging, the two absolute leaders in China's medical equipment sector, are also quietly expanding their presence.。

In March this year, Mindray revealed that its surgical robot products would enter the registration phase this year. United Imaging's thoracic and abdominal endoscopic surgery system was approved in China at the end of December last year.

The Star-Studded Competition at the Forefront of Medical Devices,The real competition has just begun.。

END